الفهرس 
Title : Safety and efficacy of intravitreal decorin preventing proliferative vitreoretinopathy following open globe injury
AbstractOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
To determine the safety, tolerability, and efficacy of human recombinant decorin protein, a transforming growth factor ß (TGFß) inhibitor in preventing proliferative vitreoretinopathy (PVR) in patients with perforating globe injuries. Patients and Methods: This is a prospective, single-center, open-label, interventional case series. A single intravitreal injection of decorin 200ug (n=4) and 400ug (n=8) was given within 24 hours of injury. Pars plana vitrectomy with silicone oil injection was done if indicated. ERG was done before injections, at day 10, and 3 months. Serial plasma decorin levels were assessed before injections, day 3, 5, and 10 post-injection. Clinical assessment included globe survival, retinal attachment rate, and PVR evaluation. Results: Twelve patients (12 eyes) with perforating globe injuries (Zone III) with best corrected visual acuities light perception or better were included. Patients with mean age of 24.5±6.09 years (range: 18-40) were followed for a median of 6 months. Intravitreal decorin administered were well tolerated with no ocularor systemic safety adverse events noted at either dose. Combined ERG b wave didn{u2019}t show any significant worsening during the study. Decorin levels started to increase in plasma at day 5 and reached 2115.33 picrograms/ml in vitreous at the time of vitrectomy. With 400 æg intravitreal decorin injection, final BCVA {u2265}20/200 was achieved in 75% with a final retinal attachment rate of 75%. PVR rate was 25% and globe survival rates were 87.5%